Supplementary Materials
The PDF file includes:
- Material and Methods
- Fig. S1. Changes in T cell subsets in patients with RRMS on teriflunomide treatment.
- Fig. S2. Influence of teriflunomide on proliferation and cytokine production.
- Fig. S3. Impact of antigen affinities and DHODH interference on proliferation.
- Fig. S4. Metabolic assessment of T cells under teriflunomide treatment.
- Fig. S5. Influence of DHODH inhibition on T cell metabolism, on gene expression of OT-I and OT-III T cells, on TH1 differentiation and proliferation, and on Treg subpopulations in EAE.
- Fig. S6. Metabolism of T cells from patients with RRMS and HCs.
- Fig. S7. Comparison of freshly isolated versus frozen PBMCs from HCs regarding immune cell subset composition and metabolism.
- Fig. S8. Additional information supporting methodology.
- Table S1. Demographics and baseline disease characteristics TERIDYNAMIC trial.
- Table S2. Differentially regulated genes depicted in Fig. 5I.
- Table S3. Demographics and baseline disease characteristics of HCs and treatment-naïve patients analyzed for TCR repertoire changes.
- Table S4. Demographics and baseline disease characteristics of treatment-naïve patients before and during teriflunomide treatment analyzed for TCR repertoire changes.
- Table S5. Demographics and baseline disease characteristics of treatment-naïve patients before and during teriflunomide treatment analyzed for immune cell phenotyping.
- Table S6. Demographics and baseline disease characteristics of patients before and during teriflunomide treatment for at least 6 months analyzed for suppressive capacity of Tregs.
- Table S7. Demographics and baseline disease characteristics of patients before and during teriflunomide treatment for at least 6 months analyzed for cytokine expression of Tregs.
- Table S8. Demographics and baseline disease characteristics of treatment-naïve patients before and during teriflunomide treatment for at least 6 months analyzed for myelin-specific T cell frequencies.
- Table S9. Demographics and baseline disease characteristics of treatment-naïve patients before and during teriflunomide treatment for at least 6 months analyzed for metabolic activity.
- Table S10. Demographics and baseline disease characteristics of treatment-naïve patients before and during treatment with DMF, IFN-β, or GLAT analyzed for TCR repertoire changes.
- Table S11. Demographics and baseline disease characteristics of HCs and treatment-naïve patients analyzed for metabolic activity.
- Table S12. Demographics and baseline disease characteristics of HCs and patients analyzed for metabolic activity after 72 hours of in vitro stimulation.
- Table S13. Demographics of HCs analyzed for immune cell phenotyping of freshly isolated versus frozen PBMCs.
- Table S14. Demographics of HCs analyzed for metabolic differences of T cells isolated from fresh blood or frozen PBMCs.
- References (36–38)
Other Supplementary Material for this manuscript includes the following:
- Data file S1 (Microsoft Excel format). Primary data.